RVMD (Revolution Medicines) Forward P/E Multiple

Official company branding of Revolution Medicines, Inc. (RVMD)

The high barrier to entry in the targeted oncology therapy sector is driven by complex patenting and costly research. The expected P/E multiple valuation for Revolution Medicines (RVMD) clearly illustrates these processes, where 0.00 serves as the current metric level. Growth potential relies on the commercialization of RAS protein inhibitors for gastrointestinal and lung therapies, as well as positive clinical trial results.

Revolution Medicines, Inc. - RVMD Forward P/E Multiple (period 07/04/2022 - 11/17/2026)

Summary analytical data breakdowns for revmed.com (RVMD)

- current price and projected stock value:
Fundamental valuation:revmed.com
Brand item of Revolution Medicines

Revolution Medicines integrates AI modeling and synthesis automation to accelerate the development of oncology drugs, which directly impacts future profitability. By analyzing the forward P/E ratio for Revolution Medicines (RVMD), an investor assesses the current stock price relative to the expected net income in one year; a sharp increase in this multiple signals inflated market expectations, while a moderate valuation confirms the fundamental resilience of the business.

Competitors of Revolution Medicines (RVMD)

Forward P/E Multiple ONC|HALO (Halozyme Inc.) - Future Price to Earnings Multiple|Forward P/E Multiple AAPG (ascentage.com)|CGON - Projected Price to Earnings|URGN: Projected Price to Earnings|BCAX - Forward P/E Multiple|Personalis Corp (PSNL) - Future Price to Earnings|Erasca Corp - Future Price to Earnings Multiple|DCTH (Delcath Systems Inc) - Forward P/E Multiple|Projected Price to Earnings Ratio Y-mAbs Therapeutics, Inc. YMAB|Forward P/E Multiple AURA|Projected Price to Earnings Candel Therapeutics, Inc. CADL|Forward P/E Multiple ARAY (Accuray, Inc.)|SELLAS Life Sciences - Future Price to Earnings|ACTU: Projected Price to Earnings|Citius Oncology, Inc. - Market Cap to Future Earnings Ratio|HURA (TuHURA Biosciences) - Projected Price to Earnings|TARA: Market Cap to Future Earnings Ratio|Projected Price to Earnings FATE|WHWK: Future Price to Earnings Multiple|Projected Price to Earnings TCRX (TScan Therapeutics Inc)|Market Cap to Projected Earnings Champions Oncology Inc|Forward P/E Multiple XBIT (XBiotech Inc.)|Future Price to Earnings Multiple CVM|OS Therapies Inc. - Forward P/E Multiple|RADX - Forward P/E Multiple|ARTV: Forward P/E Multiple|ANL: Market Cap to Future Earnings Ratio|Projected Price to Earnings VERU|TPST: Future Price to Earnings Multiple|Future Price to Earnings xiliotx.com (XLO)|Renovaro - Price to Future Earnings Ratio|Future Price to Earnings Mural Oncology MURA|KAPA - Projected Price to Earnings|OKUR - Future Price to Earnings|GDTC - Forward P/E Multiple|Curis, Inc. (CRIS) - Future Price to Earnings|Projected Price to Earnings Apollomics, Inc.|Projected Price to Earnings THAR|Price to Future Earnings Ratio ADVB (Advanced Biomed)|Projected Price to Earnings GNPX (Genprex, Inc)|CLDI: Price to Expected Earnings Ratio|Future Price to Earnings sunshinebiopharma.com SBFM|XBIO - Projected Price to Earnings|SLRX: Projected Price to Earnings|Purple Biotech - Market Cap to Future Earnings Ratio|American Oncology Network (AONC) - Future Price to Earnings|Price to Future Earnings Ratio BGNE|Projected Price to Earnings CKPT|Future Price to Earnings ELEV|Forward P/E Multiple ICAD|Forward P/E Multiple Ikena Oncology Inc. (IKNA)|Forward P/E Multiple NTBL (Notable Labs Ltd)|Market Cap to Projected Earnings Viracta Therapeutics (VIRX)|MOR: Projected Price to Earnings|NAYA (NAYA Bio) - Price to Future Earnings Ratio|AAPGV: Forward P/E Multiple